KemPharm, Inc. (KMPH): Price and Financial Metrics

KemPharm, Inc. (KMPH): $5.81

0.02 (-0.34%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add KMPH to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#128 of 401

in industry

KMPH Price/Volume Stats

Current price $5.81 52-week high $6.92
Prev. close $5.83 52-week low $4.00
Day low $5.78 Volume 64,100
Day high $5.97 Avg. volume 189,500
50-day MA $5.22 Dividend yield N/A
200-day MA $5.25 Market Cap 200.47M

KMPH Stock Price Chart Interactive Chart >


KemPharm, Inc. (KMPH) Company Bio


KemPharm Inc. provides biopharmaceutical services. The Company offers discovery and development of therapies for the treatment of attention deficit hyperactivity disorder (ADHD), pain, and cardiovascular diseases.


KMPH Latest News Stream


Event/Time News Detail
Loading, please wait...

KMPH Latest Social Stream


Loading social stream, please wait...

View Full KMPH Social Stream

Latest KMPH News From Around the Web

Below are the latest news stories about KEMPHARM INC that investors may wish to consider to help them evaluate KMPH as an investment opportunity.

Zevra Therapeutics Begins Trading as ZVRA

Company’s common stock will begin trading on the Nasdaq Global Select Market under the new ticker symbol “ZVRA” starting today, March 1, 2023 New Company name, Zevra, is Greek for zebra, the internationally recognized symbol for the rare disease community CELEBRATION, Fla., March 01, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, announced today that it will begin trading under the new tick

Yahoo | March 1, 2023

Zevra Therapeutics Reiterates Commitment to Rare Disease Community as New Corporate Council Member of the National Organization for Rare Disorders (NORD)

CELEBRATION, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, today announced that it has become a Corporate Council member of the National Organization for Rare Disorders (NORD) and reiterated its commitment to the rare disease community by celebrating Rare Disease Day 2023. A rare disease is a condition that impacts fewer than 200,000 people in the United States, with o

Yahoo | February 28, 2023

Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary Proxy

CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company” and formerly known as KemPharm, Inc.), today announced it has filed its preliminary proxy statement with the U.S. Securities and Exchange Commission (the “SEC”) in connection with the Company’s 2023 Annual Meeting of Stockholders (“Annual Meeting”), which is scheduled to take place on April 25, 2023. Stockholders do not need to take any action with respect to the 2023 Annual M

Yahoo | February 27, 2023

Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results

CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that the Company will host a conference call and live audio webcast on Tuesday, March 7, 2023, at 8:30 a.m. ET, to discuss its corporate and financial results for the fourth quarter and full-year 2022. The audio webcast with a slide presentation will be accessible via the Investor Relations section of t

Yahoo | February 27, 2023

Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium™ 2023

Interim data analysis of four-year, open-label extension from Phase 2/3 clinical trial suggests arimoclomol may reduce long-term progression of Niemann-Pick Disease Type C (NPC) CELEBRATION, Fla., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company,” formerly known as KemPharm, Inc.), today announced that arimoclomol, the Company’s orally-delivered, first-in-class investigational product candidate being developed as a treatment for Niemann-Pick di

Yahoo | February 24, 2023

Read More 'KMPH' Stories Here

KMPH Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year -61.27%
5-year -77.16%
YTD N/A
2023 0.00%
2022 -47.30%
2021 -22.23%
2020 84.55%
2019 -78.69%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!